DRUG-INDUCED OSTEONECROSIS OF THE JAWS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper gives an update on jaw osteonecrosis occurring with the use of different drugs.

Full Text

Restricted Access

About the authors

E. Basin

I.M. Sechenov First Moscow State Medical University

Email: kroko-stomatolog@mail.ru
Candidate of Medical Sciences

Yu. Medvedev

I.M. Sechenov First Moscow State Medical University

Email: kroko-stomatolog@mail.ru
Professor

K. Polyakov

I.M. Sechenov First Moscow State Medical University

Email: kroko-stomatolog@mail.ru
Candidate of Medical Sciences

References

  1. Майман Г.М. Клиника и патогенез хронической фосфорной интоксикации // Горьковский мед. журн. - 1934; 4-5: 81-105.
  2. Брунс Г.Ф. Фосфорное омертвение лицевых костей // Врач. - 1880; 1 (47): 772; 1 (49): 804-7; 1 (50): 829-35.
  3. Ruggiero S., Dodson T., Fantasia J. et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw - 2014 Update // J. Oral Maxillofac. Surg. - 2014; doi: 10.1016/j. joms.2014.04.031.
  4. Hillner B., Ingle J., Chlebowski R. et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer // J. Clin. Oncol. - 2003; 21: 4042.
  5. Saad F., Gleason D., Murray R. et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma // J. Natl. Cancer Inst. - 2002; 94: 1458.
  6. Saad F., Gleason D., Murray R. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer // J. Natl. Cancer Inst. - 2004; 96: 879.
  7. Rosen L., Gordon D., Tchekmedyian N. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial // Cancer. - 2004; 100: 2613.
  8. Rosen L., Gordon D., Kaminski M. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial // Cancer J. - 2001; 7: 377.
  9. Berenson J., Hillner B., Kyle R. et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma // J. Clin. Oncol. - 2002; 20: 3719.
  10. Physicians' Desk Reference. 57th ed. Montvale / NJ: Medical Economics, 2003.
  11. Letocha A., Cintas H., Troendle J. et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement // J. Bone Miner. Res. - 2005; 20: 977.
  12. Watts N. Bisphosphonate treatment of osteoporosis // Clin. Geriatr. Med. -2003; 19: 395.
  13. Delmas P. The use of bisphosphonates in the treatment of osteoporosis // Curr. Opin. Rheumatol. - 2005; 17: 462.
  14. Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic // J. Oral Maxillofac. Surg. - 2003; 61: 1115-7.
  15. Ruggiero S., Mehrotra B., Rosenberg T. et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases // J. Oral Maxillofac. Surg. - 2004; 62: 527-34.
  16. Bagan J., Murillo J., Jimenez Y. et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases // J. Oral Pathol. Med. -2005; 34: 120-3.
  17. Marx R., Sawatari Y., Fortin M. et al. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment // J. Oral Maxillofac. Surg. - 2005; 63: 1567-75.
  18. Durie B., Katz M., Crowley J. Osteonecrosis of the jaw and bisphosphonates // N. Engl. J. Med. - 2005; 353: 99-102.
  19. Bennett C., Nebeker J., Lyons E. et al. The Research on Adverse Drug Events and Reports (RADAR) project // JAMA. - 2005; 293: 2131-40.
  20. Qi W., Tang L., He A. et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials // Int. J. Clin. Oncol. - 2013; 19 (2): doi: 10.1007/s10147-013-0561-6.
  21. Scagliotti G., Hirsh V., Siena S. et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study // J. Thorac. Oncol. - 2012; 7: 1823.
  22. Рузин Г.П., Ткаченко О.В. Клинико-рентгенологические варианты течения остеомиелита костей лица у наркозависимых больных // Український стоматологічний альманах. - 2013; 1: 46-50.
  23. Нестеров А.П., Нестеров А.А., Хабибов Я.Т. Патогенез одонтогенного остеомиелита челюстей у лиц с зависимостью от дезоморфина // Дентал Юг. - 2012; 102 (6): 42-4.
  24. Баранник Н.Г., Варжапетян С.Д., Мосейко А.А. и др. Опыт лечения пациентов с остеомиелитом челюстей и вторичным иммунодефицитом на фоне приема наркотических препаратов. Актуальні питання медичної науки та практики: Зб. наук. пр. ДЗ «ЗМАПО МОЗ України». Запоріжжя. 2013; 1 (1) Вып. 80: 12-20.
  25. Мостовой С.О., Остапенко О.В., Шульгин В.Ф. Идентификация этиологического фактора, вызывающего «винтовые остеомилиты», и оценка его воздействия на костную ткань и мочевиделительную систему лабораторных белых крыс // Ученые записки Таврического национального университета им. В.И. Вернадского Серия «Биология, химия». - 2012; 25 (64): 244-51.
  26. Marx R. Uncovering the cause of «phossy jaw» circa 1858 to 1906: Oral and maxillofacial surgery closed case file - Case closed // J. Oral. Maxillofac. Surg. -2008; 66: 2356.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies